ContractWarrant to Purchase Stock • June 15th, 2021 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • California
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 6.3 AND 6.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • June 15th, 2021 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • California
THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) is dated as of the Effective Date among (a) SILICON VALLEY BANK, a California corporation (“SVB”), in its capacity as administrative agent and collateral agent (“Agent”), (b) SVB, as a lender, (c) SVB INNOVATION CREDIT FUND VIII, L.P., a Delaware limited partnership (“SVB Capital”), as a lender (SVB and SVB Capital and each of the other “Lenders” from time to time a party hereto are referred to herein collectively as the “Lenders” and each individually as a “Lender”), and (d) the borrower listed on Schedule I hereto (“Borrower”). The parties agree as follows:
OPTION CANCELLATION AGREEMENTOption Cancellation Agreement • June 15th, 2021 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • California
THIS OPTION CANCELLATION AGREEMENT (this “Agreement”), is entered into as of June 10, 2021 by and between INmune Bio Inc., a Nevada corporation (the “Company”), and Xencor, Inc. a Delaware corporation (“Xencor”), for the purpose of the cancellation of certain options to purchase shares of the Company’s common stock, par value $0.001 per share (“Common Stock”) held by Xencor.
FIRST AMENDMENT TO LICENSE AGREEMENTLicense Agreement • June 15th, 2021 • Inmune Bio, Inc. • Biological products, (no disgnostic substances)
This FIRST AMENDMENT TO LICENSE AGREEMENT is entered into as of the 10th day of June, 2021 (the “Amendment”) by and among INMUNE BIO, INC., a Nevada corporation (“INmune”), having a principal place of business at 1224 Prospect Street, Suite 150, La Jolla, California 92037, and XENCOR, INC., a Delaware corporation (“Xencor”), having a principal place of business at 111 West Lemon Avenue, Monrovia, California 91016, U.S.A.
